Annovis Bio (ANVS)
(Delayed Data from NYSE)
$18.01 USD
+4.41 (32.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $17.66 -0.35 (-1.94%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for Annovis Bio, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -56.20 | -25.33 | -14.49 | -5.46 | -0.99 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -0.23 | -1.14 | 0.66 | -0.40 | 0.42 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.47 | 9.15 | 4.70 | 1.89 | 0.09 |
Net Cash From Operating Activities | -39.97 | -17.31 | -9.13 | -3.97 | -0.48 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 17.34 | 0.00 | 46.74 | 12.03 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 |
Net Cash from Financing Activities | 17.34 | 0.00 | 46.74 | 12.04 | 0.44 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -22.62 | -17.31 | 37.61 | 8.07 | -0.03 |
Cash at Beginning of Period | 28.38 | 45.69 | 8.07 | 0.00 | 0.04 |
Cash at End of Period | 5.75 | 28.38 | 45.69 | 8.07 | 0.00 |
Diluted Net EPS | -6.23 | -3.10 | -1.90 | -0.87 | -3.51 |
Fiscal Year End for Annovis Bio, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -56.20 | -33.99 | -19.27 | -9.74 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | -0.23 | -0.36 | -5.07 | -3.43 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 16.47 | 3.75 | 3.11 | 1.54 |
Net Cash From Operating Activities | NA | -39.97 | -30.60 | -21.23 | -11.63 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 17.34 | 8.58 | 8.57 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.01 | 0.01 |
Net Cash from Financing Activities | NA | 17.34 | 8.58 | 8.58 | 0.01 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -22.62 | -22.02 | -12.65 | -11.62 |
Cash at Beginning of Period | NA | 28.38 | 28.38 | 28.38 | 28.38 |
Cash at End of Period | NA | 5.75 | 6.35 | 15.72 | 16.76 |
Diluted Net EPS | NA | -2.34 | -1.63 | -1.07 | -1.19 |